What Incyte Corp does.

Incyte is a global biopharmaceutical company engaged in the discovery, development and commercialization of proprietary therapeutics. Our global headquarters is located in Wilmington, Delaware, where we conduct discovery, clinical development and commercial operations. We also conduct clinical development and commercial operations from our European headquarters in Morges, Switzerland, and our other offices across Europe, as well as our Japanese headquarters in Tokyo and our Canadian headquarters in Montreal.

We are focused in three therapeutic areas that are defined by the indications of our approved medicines and the diseases for which our clinical candidates are being developed. These therapeutic areas are: Hematology, Oncology, and Inflammation and Autoimmunity (“IAI”).

Our hematology franchise includes four approved products, JAKAFI (ruxolitinib), ICLUSIG (ponatinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) and NIKTIMVO (axatilimab-csfr), as well as multiple clinical development programs.

Revenue and profit, by fiscal year.

More on INCY.

• Incyte Corp summary
• Incyte Corp financial statements
• Incyte Corp key metrics
• Incyte Corp health scores and style box
• Incyte Corp earnings
• Incyte Corp dividends
• Incyte Corp valuation
• Incyte Corp ownership and insiders
• Incyte Corp peers

Figures from Incyte Corp's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.